Stockscreener 앱 받기
0.7664
0.56%
0.0043
전일 마감가:
$0.7621
열려 있는:
$0.76
하루 거래량:
293.72K
Relative Volume:
0.25
시가총액:
$48.26M
수익:
$233.00K
순이익/손실:
$-64.61M
주가수익비율:
-0.6644
EPS:
-1.1536
순현금흐름:
$-58.32M
1주 성능:
-15.44%
1개월 성능:
-28.37%
6개월 성능:
-69.59%
1년 성능:
-52.69%
1일 변동 폭
$0.735
$0.7749
1주일 범위
$0.7319
$0.9198
52주 변동 폭
$0.7319
$3.82
코넥트 바이오파마 Stock (CNTB) Company Profile
명칭
Connect Biopharma Holdings Ltd
전화
858-727-1040
주소
3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO
Compare CNTB vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CNTB
Connect Biopharma Holdings Ltd
|
0.7664 | 48.26M | 233.00K | -64.61M | -58.32M | -1.1536 |
VRTX
Vertex Pharmaceuticals Inc
|
525.04 | 133.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.33 | 82.91B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.11 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
877.53 | 55.18B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
378.10 | 42.77B | 5.76B | 514.49M | 1.10B | 4.4813 |
코넥트 바이오파마 Stock (CNTB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-12 | 재개 | Leerink Partners | Outperform |
| 2026-06-26 | 개시 | Piper Sandler | Overweight |
| 2026-05-26 | 개시 | Canaccord Genuity | Buy |
| 2026-05-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-12-01 | 개시 | Lake Street | Buy |
| 2025-10-31 | 개시 | BTIG Research | Buy |
| 2025-06-12 | 개시 | H.C. Wainwright | Buy |
| 2024-03-04 | 개시 | H.C. Wainwright | Buy |
| 2021-04-13 | 개시 | Jefferies | Buy |
| 2021-04-13 | 개시 | Piper Sandler | Overweight |
| 2021-04-13 | 개시 | SVB Leerink | Outperform |
모두보기
코넥트 바이오파마 주식(CNTB)의 최신 뉴스
Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher - Zacks Investment Research
Alps Group (Nasdaq:ALPS)Stock Analysis - simplywall.st
A holder reports sole voting power over 400,000 Connect Biopharma (CNTB) shares, plus shared ownership. - Stock Titan
Q3 EPS Estimate for Connect Biopharma Reduced by Analyst - MarketBeat
Connect Biopharma Holdings (NasdaqGM:CNTB) Stock Forecast & Analyst Predictions - Simply Wall Street
Preliminary results at Connect Biopharma (CNTB) show fewer treatment failures but a missed lung-function target. - Stock Titan
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation - sg.finance.yahoo.com
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation - Yahoo Finance
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation - GlobeNewswire
A COPD treatment cut hospital stays and ER visits for new flare-ups by 100% vs placebo through Week 4 - Stock Titan
Connect Biopharma Holdings Limited (CNTB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Connect Biopharma Holdings (Nasdaq:CNTB)Stock Analysis - simplywall.st
CNTB Stock Pulls Back As Rademikibart Data Fuels New Catalysts - timothysykes.com
CNTB Stock Pulls Back As Rademikibart Data Fuels New Catalysts - www.timothysykes.com
FEV1 well done, will FDA Connect the phase II asthma dots? - BioWorld News
Form 8K Connect Biopharma Holdings Ltd For: 15 September By Investing.com - Investing.com Canada
Form 8K Connect Biopharma Holdings Ltd For: 15 September By Investing.com - Investing.com UK
Connect Biopharma (CNTB) asthma trial cuts failures 66% but misses main goal - Stock Titan
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation - GlobeNewswire
CNTB Stock Slides As Traders Weigh Cash Runway And Volatility - www.timothysykes.com
CNTB Stock Whipsaws As Traders Weigh Cash Runway And Losses - Timothy Sykes
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation - Yahoo Finance
An asthma drug reduced treatment failures 66%—but missed statistical significance - Stock Titan
Form 8K Connect Biopharma Holdings Ltd For: 15 September By Investing.com - Investing.com India
CNTB News | CONNECT BIOPHARMA HOLDINGS L (NASDAQ:CNTB) - ChartMill
A Sept. 15 live webcast will feature Connect Biopharma management - Stock Titan
We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate - simplywall.st
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Consensus Rating of "Moderate Buy" by Analysts - marketbeat.com
Connect Biopharma stock rating reiterated at Buy by Canaccord - Investing.com South Africa
Connect Biopharma stock rating reiterated at Buy by Canaccord - Investing.com Canada
Connect Biopharma stock rating reiterated at Buy by Canaccord - Investing.com
CCORF Maintains Connect Biopharma(CNTB.US) With Buy Rating, Raises Target Price to $7 - Moomoo
Will Connect Biopharma (CNTB) Breathe Easy After Seabreeze Trials? - RTTNews
Connect (CNTB) Financial Results: Reported EPS Misses Expectations in the Reported Period; Share Response: Shares Close 7.32% Lower on the DayPretax Income Report - https://www.dars.gov.et/
Connect Biopharma Holdings Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
HC Wainwright Issues Pessimistic Forecast for CNTB Earnings - MarketBeat
Connect Biopharma (NASDAQ:CNTB) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Ikarian Capital (CNTB) discloses 6.9% Connect Biopharma holding on Schedule 13G/A - Stock Titan
Connect Biopharma (CNTB) investor Wei Zheng discloses 4% beneficial stake - Stock Titan
Connect Biopharma Holdings Ltd expected to post a loss of 21 cents a shareEarnings Preview - TradingView
H.C. Wainwright Maintains Connect Biopharma(CNTB.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Connect Biopharma Holdings earnings beat by ¥0.33, revenue topped estimates - Investing.com Canada
Connect Biopharma Holdings earnings beat by ¥0.34, revenue topped estimates - Investing.com
Connect Biopharma Q2 Results: Net Loss Widens To $17.3 Million - scanx.trade
Connect Biopharma (NASDAQ:CNTB) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
Connect Biopharma (CNTB) ramps rademikibart spend as losses deepen in 2026 - Stock Titan
Connect Biopharma Holdings Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Connect Biopharma (CNTB) widens Q2 2026 loss as R&D rises, cash at $31.5M - Stock Titan
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update - finance.yahoo.com
코넥트 바이오파마 (CNTB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
코넥트 바이오파마 주식 (CNTB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Huang James | Director |
Mar 31 '26 |
Buy |
3.45 |
1,160,000 |
4,002,000 |
13,160,000 |
| Panacea Innovation Limited | 10% Owner |
Nov 24 '25 |
Proposed Sale |
3.00 |
2,000,000 |
6,000,000 |
0 |
| Wei Zheng | 10% Owner |
Nov 21 '25 |
Proposed Sale |
3.19 |
650,000 |
2,073,500 |
0 |
| BioFortune Inc | 10% Owner |
Nov 18 '25 |
Proposed Sale |
2.49 |
500,000 |
1,245,000 |
0 |
| Wei Zheng | 10% Owner |
Oct 01 '25 |
Proposed Sale |
1.53 |
200,000 |
305,940 |
0 |
0.72%
2.84%
자본화:
|
볼륨(24시간):